INSULIN DEGLUDEC NEW GENERATION OF LONGACTING BASAL INSULIN ANALOG LITERATURE REVIEW AND OWN DATA)
The use of rst generation basal insulin analogues has certain limitations due to their pharmacokinetic and pharmacodynamic properties, relatively high risk of hypoglycemia and inuence on the patient’s body weight, and require a strict dosage regimens associated with lifestyle limitations. Insulin degludec (Tresiba®) is a new basal insulin with an ultra-long action (up to 42 h), low variability, stable blood glucose concentration during 24 hours and provides effective glycemic control. A pharmacokinetic and pharmacodynamic prole of insulin degludec conrms its slow and continuous absorption in once daily administration, ensures the achievement of glycemic target between meals and during the night. Compared with the group of patients receiving insulin glargine, the average daily basal, average daily bolus and total daily doses of insulin degludec decrease by 14 %, 10 % and 11 %. A stable 24-hour effect of lowering blood glucose and a low hypoglycemia risk allow the exible dosing of insulin degludec (interval between injections from 8 up to 40 hours) without deterioration of glycemic control, in contrast to other basal insulin, including insulin analogues. This exibility in prescribing the dose in combination with an effective once-daily administration make insulin degludec a more convenient basal insulin and allow to improve the adherence of patients with Diabetes Mellitus type 1 and 2 to the treatment. In general, the clinical benets of robust glycemic control, the risk reduction of night hypoglycemia and a more exible dos-ing regimen of insulin degludec, overcome the psychological barriers associated with the onset of basal insulin therapy and achieve the restoration of carbohydrates metabolism in patients with Diabetes Mellitus.